TaiwanJ Pharmaceuticals Co., Ltd.

TPEX:6549 Stock Report

Market Cap: NT$737.9m

TaiwanJ Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TaiwanJ Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth49.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Apr 14
Companies Like TaiwanJ Pharmaceuticals (GTSM:6549) Are In A Position To Invest In Growth

Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

Dec 29
Will TaiwanJ Pharmaceuticals (GTSM:6549) Spend Its Cash Wisely?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TaiwanJ Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:6549 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-28-27-27N/A
3/31/202411-17-14-14N/A
12/31/202323-6-2-1N/A
9/30/202330-3813N/A
6/30/202338-7146N/A
3/31/202327-82-9-7N/A
12/31/202215-92-22-21N/A
9/30/20228-60-25-24N/A
6/30/20221-27-27-27N/A
3/31/202211-20-19-19N/A
12/31/202122-12-10-10N/A
9/30/202122-14-12-12N/A
6/30/202122-15-14-14N/A
3/31/202111-29-28-28N/A
12/31/2020N/A-42-43-41N/A
9/30/2020N/A-47-47-46N/A
6/30/2020N/A-51-52-50N/A
3/31/202031-28-18-17N/A
12/31/201962-51517N/A
9/30/201962-761214N/A
6/30/201962-147911N/A
3/31/201931-193-54-54N/A
12/31/2018N/A-238-118-118N/A
9/30/2018N/A-195-133-133N/A
6/30/2018N/A-152-149-149N/A
3/31/2018N/A-169N/A-162N/A
12/31/2017N/A-186N/A-175N/A
9/30/2017N/A-210N/A-197N/A
6/30/2017N/A-234N/A-219N/A
3/31/2017N/A-228N/A-210N/A
12/31/2016N/A-223N/A-202N/A
9/30/2016N/A-199N/A-171N/A
6/30/2016N/A-176N/A-141N/A
3/31/2016N/A-159N/A-148N/A
12/31/2015N/A-142N/A-155N/A
9/30/2015N/A-128N/A-153N/A
6/30/2015N/A-114N/A-150N/A
3/31/2015N/A-106N/A-120N/A
12/31/2014N/A-98N/A-90N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6549's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 6549's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 6549's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 6549's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 6549's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6549's Return on Equity is forecast to be high in 3 years time


Discover growth companies